EUVIMEDEUVIMED entdecken
Crossref

Evaluation of early prophylactic corticosteroid administration on early safety and efficacy outcomes of adeno-associated virus gene therapy in the hemophilia dog model

Paul Batty, Laura L Swystun, Britta Handyside, Alexandre Menard, Lori Harpell, David Hurlbut, A M Ismail, Aomei Mo, Abbey Pender, Sebastian Brennan, Andrew Winterborn, Bridget Yates und 2 weitere

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.08.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Paul Batty und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; Department of Haematology, Cancer Institute, Universit…. Hauptthemen laut MEDLINE: Hemophilia A, Genetic Therapy, Dependovirus, Factor VIII. Die Arbeit nennt 30 Literaturangaben. Gefördert von: BioMarin Pharmaceutical, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prior to commercial withdrawal, adeno-associated virus (AAV) gene therapy was approved for the treatment of adults with severe hemophilia A. Mechanisms underlying variability, durability, and liver transaminitis are largely uncharacterized. OBJECTIVES: To evaluate the effects of prophylactic corticosteroid administration on AAV gene therapy outcomes in dogs with severe hemophilia A. METHODS: Seven dogs with hemophilia A received 6e13 vector genomes/kg of AAV5-canine factor (F)VIII. Four dogs received oral prednisolone (1 mg/kg/day) starting 3 hours preinfusion with dose-tapering over 6 weeks; three control dogs received no corticosteroids. Percutaneous liver biopsies were performed on detection of alanine aminotransferase (ALT) >2-fold the upper limit of normal. RESULTS: All dogs expressed therapeutic FVIII:C (8.7-56.1%), improved whole blood clot time, and decreased bleeding rates (pre = 6.11 vs post = 1.42 bleeds/year, P = .016) over 2 years post-AAV5-canine FVIII. Corticosteroid-treated dogs demonstrated a modest increase in mean FVIII:C at 2 years by chromogenic substrate assay (39.1%) compared with controls (29.5%), driven by one female with markedly elevated FVIII:C from day 54 onward. When analyzed by sex, all female dogs exhibited increased mean FVIII:C chromogenic substrate assay at 2 years (49.3%) compared with males (9.1%), regardless of prophylactic corticosteroid use. Prophylactic corticosteroids did not impact transient posttreatment elevations of proinflammatory cytokines, anti-AAV antibody formation, or ALT levels. One corticosteroid-treated dog experienced ALT > 4.3-fold the upper limit of normal at 18 weeks without impacting long-term FVIII:C expression. A liver biopsy showed diffuse, minimal periportal lymphocyte and neutrophil infiltration, consistent with nonspecific minimal hepatitis. CONCLUSIONS: Prophylactic corticosteroids were not clearly associated with increased transgene expression in dogs with hemophilia A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AGenetic TherapyDependovirusFactor VIIIPrednisoloneAdrenal Cortex HormonesAnimalsDogsMaleGene Therapy AgentsFemaleDisease Models, AnimalLiverGenetic VectorsTime FactorsAlanine TransaminaseTreatment OutcomeHemorrhageBlood Coagulation

Stichwörter der Autor:innen

adeno-associated viruscorticosteroidsfactor VIIIgenetic therapyhemophilia A

Substanzen

Factor VIIIPrednisoloneAdrenal Cortex HormonesAlanine Transaminase

Autor:innen und Institutionen

  • Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; Department of Haematology, Cancer Institute, University College London, London, UK.
  • Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • BioMarin Pharmaceutical, Novato, California, USA.
  • Diagnostic Radiology, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
  • Animal Care Services, Queen's University, Kingston, Ontario, Canada.
  • Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada; BioMarin Pharmaceutical, Novato, California, USA.

Förderung

  • BioMarin Pharmaceutical
  • Canadian Institutes of Health Research

Zitieren

APA

Batty, P., Swystun, L. L., Handyside, B., Menard, A., Harpell, L., Hurlbut, D., Ismail, A. M., Mo, A., Pender, A., Brennan, S., Winterborn, A., Yates, B., Fong, S., & Lillicrap, D. (2026). Evaluation of early prophylactic corticosteroid administration on early safety and efficacy outcomes of adeno-associated virus gene therapy in the hemophilia dog model. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.08.014

Vancouver

Batty P, Swystun LL, Handyside B, Menard A, Harpell L, Hurlbut D, et al. Evaluation of early prophylactic corticosteroid administration on early safety and efficacy outcomes of adeno-associated virus gene therapy in the hemophilia dog model. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.08.014

BibTeX
@article{Batty2026,
  author = {Batty, Paul and Swystun, Laura L and Handyside, Britta and Menard, Alexandre and Harpell, Lori and Hurlbut, David and Ismail, A M and Mo, Aomei and Pender, Abbey and Brennan, Sebastian and Winterborn, Andrew and Yates, Bridget and Fong, Sylvia and Lillicrap, David},
  title = {Evaluation of early prophylactic corticosteroid administration on early safety and efficacy outcomes of adeno-associated virus gene therapy in the hemophilia dog model},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.08.014}
}
Kostenlos starten →